

# BAMBINO AGRO INDUSTRIES LTD.



04<sup>th</sup> July, 2020

To,  
The Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001

Scrip Code: 519295

Dear Sir/Madam,

**Sub: Newspaper Publication of intimation of Board Meeting**  
**Ref: Regulation 47 of SEBI (LODR) Regulations, 2015**

Further to our letter dated 03<sup>rd</sup> July, 2020, please find enclosed the newspaper publication of the intimation of Notice of re-scheduled Board Meeting to be held on Thursday, 30<sup>th</sup> July, 2020 in Business Standard (All Editions) and Nava Telangana (Hyderabad Edition) on 04<sup>th</sup> July, 2020.

This is for your information and record purpose.

Yours Faithfully,  
For Bambino Agro Industries Limited

Ritu Tiwary  
Company Secretary

Encl.: a/a

**WE BRING HEALTH TASTE AND CONVENIENCE TO LIFE**

4E, Surya Towers, Sardar Patel Road, Secunderabad-500 003. Phone : 4436 3322 & 2781 6611  
Fax : +91 - 40 - 2781 6615, E-mail : ho.hr@bambinoagro.com  
CIN : L15440TG1980PLC004363 WWW.bambinofood.com

# Covid vaccine race goes to booster as field widens

More competitors get DCGI nod to advance to clinical trial stage

VINAY UMARJI & SOHINI DAS  
Ahmedabad/Mumbai, 3 July

The race to develop a vaccine for SARS-Cov-2 (novel coronavirus) just got hotter as more competitors received regulatory approval from the Drugs Controller General of India's (DCGI's) Central Drugs Standard Control Organisation (CDSCO) to conduct phase-II clinical human trials.

Recently, Bharat Biotech's Covaxin, a vaccine candidate that it developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV), was approved for human trials, making it the first indigenously developed vaccine to get the nod.

To develop Covaxin, NIV Pune isolated the virus strain and transferred it to Bharat Biotech. And the vaccine has shown positive results in pre-clinical animal trials.

On Thursday, CDSCO also approved Zydus Cadila's plasmid DNA vaccine candidate ZyCoV-D, developed at its Vaccine Technology Centre in Ahmedabad.

With the ICMR setting August 15 as the deadline to launch a Covid-19 vaccine, Zydus Cadila intends to ramp up production capacities of ZyCoV-D to cater to Indian and global demand.

The firm said the vaccine elicited a strong immune response in mice, rats,



The University of Oxford and AstraZeneca's experimental vaccine has entered the final stage of clinical trials. Scientists have initiated clinical trials in 5 Africa, while the Indian partner, Serum Institute of India, is hopeful it will be made available by year-end

guinea pigs, and rabbits. "The antibodies produced by the vaccine were able to completely neutralise the wild type virus... indicating the protective potential of the vaccine candidate," Cadila Healthcare said in an official communiqué on Friday.

Meanwhile, the University of Oxford and AstraZeneca's experimental Covid-19 vaccine has entered the final stage of clinical trials. Scientists have initiated clinical trials in South Africa, while the Indian partner, Serum Institute of India (SII), is hopeful it will be made available by year-end.

Scientists at the University of Witwatersrand have started clinical trials in South Africa with the team set to test the 'Ox1Cov-19' or 'Oxford Vaccine'. Adar Poonawalla, chief executive officer of Serum Institute, has said the company

will need to conduct phase-III clinical trials here before launching the vaccine.

Apart from partnering with AstraZeneca to supply a billion doses of Oxford's potential vaccine to low and middle-income countries, Serum Institute is also working on a recombinant BCG vaccine as an immunity booster against respiratory viruses. Trials for this are on in India, and the first batch might go into production by August-September.

Indian Immunologicals (IIL) is also conducting preclinical trials on small animals and non-human primates. However, according to the company's Managing Director Anand Kumar, these trials could go on till December. The company is working on a live-attenuated weakened placid vaccine candidate that almost resembles the Covid-19

Re  
no

Early c  
manag  
results  
eries, v  
naviru  
cent in  
Union  
The  
patient  
minist  
India's  
over 2  
time, 1  
6,25,5-  
the di  
379 ne

virus, bu  
multipl  
How  
success  
to colla  
facture  
else con  
us we ar  
for man  
up with  
capacity  
for man  
tion, the  
facturer  
are talki  
the tech  
with ou  
Business

## BAMBINO AGRO INDUSTRIES LIMITED

CIN No: L15440TG1983PLC004363; 4E, Surya Towers, S.P. Road, Secunderabad-500 003.  
Ph No: 040-44363322; Email id: cs@bambinoagro.com

### POSTPONEMENT OF BOARD MEETING

Reference to our adv dt 18th June 2020 regarding conducting of Board Meeting for consideration of audited financial results for the quarter and year ended 31.03.2020 and recommendation of dividend, if any, to be held on 26th June 2020, please note that the said meeting shall now be held on **Thursday, the 30th July 2020** at the registered office of the Company in due compliance of recent SEBI Circular granting further extension.

For BAMBINO AGRO INDUSTRIES LIMITED  
M. KISHAN RAO

Place : Secunderabad  
Dated: 03-07-2020

Chairman & Managing Director  
DIN No: 02425967



## PRANAVADITYA SPINNING MILLS LIMITED

CIN: L17119PN1990PLC058139

Registered Office: Office No. 2, Plot No. 266, Village Atte, Kumbhoj Road, Taluka Hatkanangale, District Kolhapur 416 109, Maharashtra.  
Tel No. (230) 2463100 / 2461929

Website: [www.pranavaditya.com](http://www.pranavaditya.com); E-mail: [investors@pranavaditya.com](mailto:investors@pranavaditya.com)

### NOTICE TO THE MEMBERS WITH RESPECT TO THE 30<sup>th</sup> ANNUAL GENERAL MEETING

NOTICE is hereby given that the 30<sup>th</sup> Annual General Meeting ("AGM") of the members of Pranavaditya Spinning Mills Limited ("the Company") will be held on **Wednesday, July 29, 2020 at 12.30 p.m. (IST)** through Video Conferencing ("VC") or other Audio Visual Means ("OAVM"), to transact the business as set out in the Notice of the AGM which will be emailed to the members of the Company.

